CN111386285B - 增强fx活化的因子x结合物 - Google Patents

增强fx活化的因子x结合物 Download PDF

Info

Publication number
CN111386285B
CN111386285B CN201880073999.9A CN201880073999A CN111386285B CN 111386285 B CN111386285 B CN 111386285B CN 201880073999 A CN201880073999 A CN 201880073999A CN 111386285 B CN111386285 B CN 111386285B
Authority
CN
China
Prior art keywords
antibody
binding fragment
antigen
antigen binding
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880073999.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111386285A (zh
Inventor
J·伦德
K·索恩
M·N·哈恩达尔
M-A·拜塞
E·D·塔弗尼尔
S·斯蒂芬森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN202411097090.0A priority Critical patent/CN118745229A/zh
Publication of CN111386285A publication Critical patent/CN111386285A/zh
Application granted granted Critical
Publication of CN111386285B publication Critical patent/CN111386285B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880073999.9A 2017-11-15 2018-11-15 增强fx活化的因子x结合物 Active CN111386285B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411097090.0A CN118745229A (zh) 2017-11-15 2018-11-15 增强fx活化的因子x结合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17201762.6 2017-11-15
EP17201762 2017-11-15
EP18174634 2018-05-28
EP18174634.8 2018-05-28
PCT/EP2018/081296 WO2019096874A1 (en) 2017-11-15 2018-11-15 Factor x binders enhancing fx activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411097090.0A Division CN118745229A (zh) 2017-11-15 2018-11-15 增强fx活化的因子x结合物

Publications (2)

Publication Number Publication Date
CN111386285A CN111386285A (zh) 2020-07-07
CN111386285B true CN111386285B (zh) 2024-08-27

Family

ID=64426877

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880073999.9A Active CN111386285B (zh) 2017-11-15 2018-11-15 增强fx活化的因子x结合物
CN202411097090.0A Pending CN118745229A (zh) 2017-11-15 2018-11-15 增强fx活化的因子x结合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411097090.0A Pending CN118745229A (zh) 2017-11-15 2018-11-15 增强fx活化的因子x结合物

Country Status (7)

Country Link
US (2) US11787874B2 (cg-RX-API-DMAC10.html)
EP (2) EP4667496A3 (cg-RX-API-DMAC10.html)
JP (2) JP7841846B2 (cg-RX-API-DMAC10.html)
CN (2) CN111386285B (cg-RX-API-DMAC10.html)
ES (1) ES3050257T3 (cg-RX-API-DMAC10.html)
MA (1) MA50893A (cg-RX-API-DMAC10.html)
WO (1) WO2019096874A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN111386285B (zh) * 2017-11-15 2024-08-27 诺和诺德股份有限公司 增强fx活化的因子x结合物
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US12258406B2 (en) * 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
JP2025518552A (ja) * 2022-05-16 2025-06-17 セリントラ・セラピューティクス・エスア 細胞を操作するための組成物及び方法
MA71385A (fr) * 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
CN115960227B (zh) * 2022-11-08 2026-06-16 河南赛诺特生物技术有限公司 一种抗人msh2的单克隆抗体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890369A (zh) * 2003-10-10 2007-01-03 中外制药株式会社 替代功能蛋白质的双特异性抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
JPH08510555A (ja) 1993-07-01 1996-11-05 デイド、インターナショナル、インコーポレイテッド 第ｘ因子除去血漿の調製のための方法
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
TW201625299A (zh) * 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
CN111386285B (zh) * 2017-11-15 2024-08-27 诺和诺德股份有限公司 增强fx活化的因子x结合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890369A (zh) * 2003-10-10 2007-01-03 中外制药株式会社 替代功能蛋白质的双特异性抗体

Also Published As

Publication number Publication date
US20230416404A1 (en) 2023-12-28
US11787874B2 (en) 2023-10-17
JP2021502984A (ja) 2021-02-04
CN111386285A (zh) 2020-07-07
EP3710486B1 (en) 2025-10-08
MA50893A (fr) 2020-09-23
US20210054097A1 (en) 2021-02-25
ES3050257T3 (en) 2025-12-19
WO2019096874A1 (en) 2019-05-23
EP3710486C0 (en) 2025-10-08
EP4667496A2 (en) 2025-12-24
EP3710486A1 (en) 2020-09-23
CN118745229A (zh) 2024-10-08
JP7841846B2 (ja) 2026-04-07
EP4667496A3 (en) 2026-06-03
JP2026040534A (ja) 2026-03-09

Similar Documents

Publication Publication Date Title
US11787874B2 (en) Factor X binders enhancing FX activation
JP7862151B2 (ja) 血液凝固抗体
CN112513096B (zh) 改进的促凝血抗体
CN115052898B (zh) 双特异性因子viii模拟抗体
US20160297892A1 (en) Novel Methods and Antibodies for Treating Coagulapathy
CN105473619B (zh) 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
US20210238306A1 (en) Procoagulant antibodies
RU2810748C2 (ru) Усовершенствованные прокоагулянтные антитела
RU2810094C2 (ru) Прокоагулянтные антитела
TW201617371A (zh) 針對經活化之因子ｖ之抗體
BR112021000823B1 (pt) ANTICORPOS PRÓ-COAGULANTES CAPAZES DE ESTIMULAR A ATIVIDADE ENZIMÁTICA DE FIXa EM DIREÇÃO A FX, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS DITOS ANTICORPOS E SEU USO NO TRATAMENTO DA HEMOFILIA A

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Tanba

Applicant after: NOVO NORDISK A/S

Address before: Tanba

Applicant before: NOVO NORDISK A/S

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant